{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:56:13Z","timestamp":1777859773903,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Achieving \u226590% improvement in Psoriasis Area and Severity Index (PASI90) is achievable with newer biologic therapies, such as ixekizumab. Standard of care payment systems such as the Merit-based Incentive Payment System (MIPS) responder criteria could lead to under treatment and lower quality of life (QoL) outcomes compared with PASI90.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Show PASI90 is a higher standard than MIPS and is associated with greater improvements in QoL and other PRO outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderate-to-severe psoriasis meeting PASI90 and MIPS criteria were compared in 3 phase 3 clinical trials of the interleukin-17A inhibitor ixekizumab (pooled UNCOVER-2\/3 and IXORA-S). Patients satisfying MIPS criteria met either static Physician Global Assessment score \u22642, body surface area &lt;3%, PASI &lt;3, or Dermatology Life Quality Index \u22645. Improvements in QoL were compared between patients meeting PASI90 and MIPS criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All PASI90 responders were also MIPS responders (PASI90 responders). Not all MIPS responders met PASI90 (MIPS-only responders). Significantly larger change from baseline improvements for all health (skin pain, Itch NRS, DLQI, PtGA, WPAI-PsO work productivity loss, and WPAI-PsO activity impairment) and quality of life (EQ-5D 5L VAS and acute SF-36 PCS\/MCS) outcome measures were observed in the PASI90 responders vs the MIPS-only responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PASI90 is a higher standard of response than MIPS and is associated with greater improvements in health and quality of life outcome measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24755303221082623","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T05:42:47Z","timestamp":1650346967000},"page":"140-149","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures"],"prefix":"10.1177","volume":"7","author":[{"given":"Jason E.","family":"Hawkes","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California-Davis, Sacramento, CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Reis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Muram","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Eastman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"bibr1-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0075-1"},{"key":"bibr2-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11099.x"},{"key":"bibr3-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354"},{"key":"bibr4-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"bibr5-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426"},{"key":"bibr6-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16736"},{"key":"bibr7-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"bibr8-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"bibr9-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"bibr10-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"bibr11-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.039"},{"key":"bibr12-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"issue":"3","key":"bibr13-24755303221082623","first-page":"10","volume":"101","author":"Golbari NM","year":"2018","journal-title":"Cutis"},{"key":"bibr14-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"bibr15-24755303221082623","first-page":"77008","volume":"81","author":"Centers for Medicare &amp; Medicaid Services","year":"2016","journal-title":"Fed Regist"},{"key":"bibr16-24755303221082623","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2947"},{"key":"bibr17-24755303221082623","volume-title":"Measure ID #410: Psoriasis: Clinical Response to Oral Systemic or Biologic Medications \u2013 National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes. [On-Line]. 2017; 2.0:2018 Options For Individual Measures","author":"Quality Payment Program cms","year":"2019"},{"key":"bibr18-24755303221082623","volume-title":"Quality Payment Program","author":"MIPS Overview","year":"2019"},{"key":"bibr19-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.03.669"},{"key":"bibr20-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"bibr21-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017"},{"key":"bibr22-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13452"},{"key":"bibr23-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1159\/000329026"},{"key":"bibr24-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"bibr25-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14211"},{"key":"bibr26-24755303221082623","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00340-3"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303221082623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303221082623","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303221082623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:23Z","timestamp":1777509443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303221082623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1177\/24755303221082623"],"URL":"https:\/\/doi.org\/10.1177\/24755303221082623","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}